CATALYSTBenzinga • 1d ago
Morgan Stanley Maintains Equal-Weight on Genmab, Raises Price Target to $57Morgan Stanley analyst Judah Frommer maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and raises the price target from $42 to $57.
Why GMAB Stock slipped -1.40% Today — RQD Quant Desk Flash
$56.49 -1.40% NASDAQ • Public Delayed / 60s Snapshot
Genmab A/S ADS (GMAB) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C • HOLD / WATCH
Cap $35.25B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
WHALE OPTIONS TUG-OF-WAR:54% Call Buyers ($3.4M)
46% PutsMax Pain: $55.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GMAB Stock slipped -1.40% Today — RQD Quant Desk Flash
Genmab A/S ADS (GMAB) slipped -1.40% to $56.49 as options desks priced 54% call premium vs. 46% put protection around the $55 max-pain magnet. Solid 41% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 90% of its 52-week range ($23.62 – $59.97) with RSI-14 at 87.6 (OVERBOUGHT (>70)).
- ▸Whale Options Positioning: $3.4M in bullish call flow vs. $2.9M in put flow (Put/Call 0.86x, implied earnings swing ±7.2%).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 41% gross margin and $779.1M annual free cash flow.
Live GMAB Headlines & Catalysts
CATALYSTSeekingAlpha • 1d ago
AbbVie: Why I See More Upside After Q3AbbVie posts strong Q3 growth, Skyrizi sales surge, and 2026 EPS guidance rises. Click for this ABBV earnings update.
CATALYSTBenzinga • 2d ago
Guggenheim Maintains Buy on Genmab, Raises Price Target to $80Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $58 to $80.
MARKET WIREYahoo • 2d ago
Can Genmab (CPSE:GMAB) Still Be Undervalued After Its Trial Wins?Genmab has seen a sharp rerating on the back of recent oncology trial successes, which puts a fresh spotlight on whether the current share price lines up with the cash flows its pipeline may ultimately produce. With the
MARKET WIREYahoo • 2d ago
Genmab’s bispecific halves risk of death in first-line HNSCCGenmab is going to approach global agencies based on the interim Phase III data for its bispecific in first-line HNSCC.
CATALYSTYahoo • 2d ago
Genmab soars to record highs after cancer drug succeeds in key trialThe drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.
CATALYSTSeekingAlpha • 2d ago
Genmab: Why I'd Wait Before Buying After A Stunning Series Of Study ResultsGenmab stock surged on strong Phase 3 cancer data, but valuation and patent risks remain. Click here to read this recent analysis of GMAB stock.
CATALYSTBenzinga • 2d ago
Truist Securities Reiterates Buy on Genmab, Raises Price Target to $67Truist Securities analyst Gregory Renza reiterates Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $45 to $67.
CATALYSTBenzinga • 3d ago
HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $70HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $50 to $70.
CATALYSTYahoo • 3d ago
Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?Investors responded positively to stronger financial performance and progress in medical research.
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live GMAB Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
GMAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +115.16%▲ ASCENDING CHANNEL
2026-10-30O $57.40H $59.02L $56.53C $57.06VOL 8.65M
RES: $60.56SUP: $36.29SMA50: $37.12SMA200: $30.50
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GMAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth
vs. +22.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on GMAB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GMAB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GMAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
GMAB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GMAB stock moving today?
Why GMAB Stock slipped -1.40% Today — RQD Quant Desk Flash. Solid 41% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.